Allogeneic stem cell transplantation in AML with t(6;9)(p23;q34);DEK-NUP214 shows a favourable outcome when performed in first complete remission

M. Diaz-Beya; M. Labopin; J. Maertens; M. Alijurf; J. Passweg; B. Dietrich; H. Schouten; G. Socie; N. Schaap; R. Schwerdtfeger; L. Volin; M. Michallet; E. Polge; J. Sierra; M. Mohty; J. Esteve; A. Nagler; European Society for Blood and Marrow Transplantation Lymphoma and Chronic Malignancies Working Parties

doi:10.1111/bjh.16433

Allogeneic stem cell transplantation in AML with t(6;9)(p23;q34);DEK-NUP214 shows a favourable outcome when performed in first complete remission

M. Diaz-Beya, M. Labopin, J. Maertens, M. Alijurf, J. Passweg, B. Dietrich, H. Schouten, G. Socie, N. Schaap, R. Schwerdtfeger, L. Volin, M. Michallet, E. Polge, J. Sierra, M. Mohty, J. Esteve^*, A. Nagler, European Society for Blood and Marrow Transplantation Lymphoma and Chronic Malignancies Working Parties

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Acute myeloid leukaemia (AML) with t(6;9)(p23;q34) is a poor-risk entity, commonly associated with FLT3-ITD (internal tandem duplication). Allogeneic stem-cell tranplantation (allo-SCT) is recommended, although studies analysing the outcome of allo-SCT in this setting are lacking. We selected 195 patients with t(6;9) AML, who received a first allo-SCT between 2000 and 2016 from the EBMT (European Society for Blood and Marrow Transplantation) registry. Disease status at time of allo-SCT was the strongest independent prognostic factor, with a two-year leukaemia-free survival and relapse incidence of 57% and 19% in patients in CR1 (first complete remission), 34% and 33% in CR2 (second complete remission), and 24% and 49% in patients not in remission, respectively (P < 0 center dot 001). This study, which represents the largest one available in t(6;9) AML, supports the recommendation to submit these patients to allo-SCT in CR1.

Original language	English
Pages (from-to)	920-925
Number of pages	6
Journal	British Journal of Haematology
Volume	189
Issue number	5
DOIs	https://doi.org/10.1111/bjh.16433
Publication status	Published - 1 Jun 2020

Keywords

9) aml
acute myeloid-leukemia
allo-sct
aml
blood
classification
dek-nup214
european-society
internal tandem duplication
prognosis
t(6
working party
AML
INTERNAL TANDEM DUPLICATION
9) AML
PROGNOSIS
CLASSIFICATION
ACUTE MYELOID-LEUKEMIA
EUROPEAN-SOCIETY
WORKING PARTY
allo-SCT
DEK-NUP214
BLOOD

Access to Document

10.1111/bjh.16433

Cite this

Diaz-Beya, M., Labopin, M., Maertens, J., Alijurf, M., Passweg, J., Dietrich, B., Schouten, H., Socie, G., Schaap, N., Schwerdtfeger, R., Volin, L., Michallet, M., Polge, E., Sierra, J., Mohty, M., Esteve, J., Nagler, A., & European Society for Blood and Marrow Transplantation Lymphoma and Chronic Malignancies Working Parties (2020). Allogeneic stem cell transplantation in AML with t(6;9)(p23;q34);DEK-NUP214 shows a favourable outcome when performed in first complete remission. British Journal of Haematology, 189(5), 920-925. https://doi.org/10.1111/bjh.16433

@article{408736ca5adc4ce6aab336e32bc9f09c,

title = "Allogeneic stem cell transplantation in AML with t(6;9)(p23;q34);DEK-NUP214 shows a favourable outcome when performed in first complete remission",

abstract = "Acute myeloid leukaemia (AML) with t(6;9)(p23;q34) is a poor-risk entity, commonly associated with FLT3-ITD (internal tandem duplication). Allogeneic stem-cell tranplantation (allo-SCT) is recommended, although studies analysing the outcome of allo-SCT in this setting are lacking. We selected 195 patients with t(6;9) AML, who received a first allo-SCT between 2000 and 2016 from the EBMT (European Society for Blood and Marrow Transplantation) registry. Disease status at time of allo-SCT was the strongest independent prognostic factor, with a two-year leukaemia-free survival and relapse incidence of 57% and 19% in patients in CR1 (first complete remission), 34% and 33% in CR2 (second complete remission), and 24% and 49% in patients not in remission, respectively (P < 0 center dot 001). This study, which represents the largest one available in t(6;9) AML, supports the recommendation to submit these patients to allo-SCT in CR1.",

keywords = "9) aml, acute myeloid-leukemia, allo-sct, aml, blood, classification, dek-nup214, european-society, internal tandem duplication, prognosis, t(6, working party, AML, INTERNAL TANDEM DUPLICATION, 9) AML, PROGNOSIS, CLASSIFICATION, ACUTE MYELOID-LEUKEMIA, EUROPEAN-SOCIETY, WORKING PARTY, allo-SCT, DEK-NUP214, BLOOD",

author = "M. Diaz-Beya and M. Labopin and J. Maertens and M. Alijurf and J. Passweg and B. Dietrich and H. Schouten and G. Socie and N. Schaap and R. Schwerdtfeger and L. Volin and M. Michallet and E. Polge and J. Sierra and M. Mohty and J. Esteve and A. Nagler and {European Society for Blood and Marrow Transplantation Lymphoma and Chronic Malignancies Working Parties}",

note = "Funding Information: This study was supported (in part) by grants from Fondo de Investigaciones Sanitarias/Instituto de Salud Carlos III (ISCIII): PI16/01027 (MDB, JE), PERIS from Generalitat de Catalunya SLT002/16/00433 (MDB, JS, JE), and 2017 SGR 1655 (MDB, JE). Funding Information: This study was supported (in part) by grants from Fondo de Investigaciones Sanitarias/Instituto de Salud Carlos III (ISCIII): PI16/01027 (MDB, JE), PERIS from Generalitat de Catalunya SLT002/16/00433 (MDB, JS, JE), and 2017 SGR 1655 (MDB, JE). Publisher Copyright: {\textcopyright} 2020 British Society for Haematology and John Wiley & Sons Ltd",

year = "2020",

month = jun,

day = "1",

doi = "10.1111/bjh.16433",

language = "English",

volume = "189",

pages = "920--925",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "Wiley",

number = "5",

}

Diaz-Beya, M, Labopin, M, Maertens, J, Alijurf, M, Passweg, J, Dietrich, B, Schouten, H, Socie, G, Schaap, N, Schwerdtfeger, R, Volin, L, Michallet, M, Polge, E, Sierra, J, Mohty, M, Esteve, J, Nagler, A & European Society for Blood and Marrow Transplantation Lymphoma and Chronic Malignancies Working Parties 2020, 'Allogeneic stem cell transplantation in AML with t(6;9)(p23;q34);DEK-NUP214 shows a favourable outcome when performed in first complete remission', British Journal of Haematology, vol. 189, no. 5, pp. 920-925. https://doi.org/10.1111/bjh.16433

TY - JOUR

T1 - Allogeneic stem cell transplantation in AML with t(6;9)(p23;q34);DEK-NUP214 shows a favourable outcome when performed in first complete remission

AU - Diaz-Beya, M.

AU - Labopin, M.

AU - Maertens, J.

AU - Alijurf, M.

AU - Passweg, J.

AU - Dietrich, B.

AU - Schouten, H.

AU - Socie, G.

AU - Schaap, N.

AU - Schwerdtfeger, R.

AU - Volin, L.

AU - Michallet, M.

AU - Polge, E.

AU - Sierra, J.

AU - Mohty, M.

AU - Esteve, J.

AU - Nagler, A.

AU - European Society for Blood and Marrow Transplantation Lymphoma and Chronic Malignancies Working Parties

N1 - Funding Information: This study was supported (in part) by grants from Fondo de Investigaciones Sanitarias/Instituto de Salud Carlos III (ISCIII): PI16/01027 (MDB, JE), PERIS from Generalitat de Catalunya SLT002/16/00433 (MDB, JS, JE), and 2017 SGR 1655 (MDB, JE). Funding Information: This study was supported (in part) by grants from Fondo de Investigaciones Sanitarias/Instituto de Salud Carlos III (ISCIII): PI16/01027 (MDB, JE), PERIS from Generalitat de Catalunya SLT002/16/00433 (MDB, JS, JE), and 2017 SGR 1655 (MDB, JE). Publisher Copyright: © 2020 British Society for Haematology and John Wiley & Sons Ltd

PY - 2020/6/1

Y1 - 2020/6/1

N2 - Acute myeloid leukaemia (AML) with t(6;9)(p23;q34) is a poor-risk entity, commonly associated with FLT3-ITD (internal tandem duplication). Allogeneic stem-cell tranplantation (allo-SCT) is recommended, although studies analysing the outcome of allo-SCT in this setting are lacking. We selected 195 patients with t(6;9) AML, who received a first allo-SCT between 2000 and 2016 from the EBMT (European Society for Blood and Marrow Transplantation) registry. Disease status at time of allo-SCT was the strongest independent prognostic factor, with a two-year leukaemia-free survival and relapse incidence of 57% and 19% in patients in CR1 (first complete remission), 34% and 33% in CR2 (second complete remission), and 24% and 49% in patients not in remission, respectively (P < 0 center dot 001). This study, which represents the largest one available in t(6;9) AML, supports the recommendation to submit these patients to allo-SCT in CR1.

AB - Acute myeloid leukaemia (AML) with t(6;9)(p23;q34) is a poor-risk entity, commonly associated with FLT3-ITD (internal tandem duplication). Allogeneic stem-cell tranplantation (allo-SCT) is recommended, although studies analysing the outcome of allo-SCT in this setting are lacking. We selected 195 patients with t(6;9) AML, who received a first allo-SCT between 2000 and 2016 from the EBMT (European Society for Blood and Marrow Transplantation) registry. Disease status at time of allo-SCT was the strongest independent prognostic factor, with a two-year leukaemia-free survival and relapse incidence of 57% and 19% in patients in CR1 (first complete remission), 34% and 33% in CR2 (second complete remission), and 24% and 49% in patients not in remission, respectively (P < 0 center dot 001). This study, which represents the largest one available in t(6;9) AML, supports the recommendation to submit these patients to allo-SCT in CR1.

KW - 9) aml

KW - acute myeloid-leukemia

KW - allo-sct

KW - aml

KW - blood

KW - classification

KW - dek-nup214

KW - european-society

KW - internal tandem duplication

KW - prognosis

KW - t(6

KW - working party

KW - AML

KW - INTERNAL TANDEM DUPLICATION

KW - 9) AML

KW - PROGNOSIS

KW - CLASSIFICATION

KW - ACUTE MYELOID-LEUKEMIA

KW - EUROPEAN-SOCIETY

KW - WORKING PARTY

KW - allo-SCT

KW - DEK-NUP214

KW - BLOOD

U2 - 10.1111/bjh.16433

DO - 10.1111/bjh.16433

M3 - Article

C2 - 32020596

SN - 0007-1048

VL - 189

SP - 920

EP - 925

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 5

ER -